Zhi-Jun Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zhi-Jun Sun has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Roger Arthur Zwahlen
Discipline of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Hong Kong, Hong Kong SAR, PR China
4 shared publications Yu Cai
The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei‐MOST) & Key Laboratory of Oral Biomedical Engineering of Ministry of Education
3 shared publications- Ashok B. Kulkarni
Functional Genomics Section, Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
2 shared publications - Xinming Chen
Department of Oral Pathology, School of Stomatology, Wuhan University, Wuhan, China
2 shared publications Yi-Fang Zhao
2 shared publications- Yi-Fang Zhao
Wuhan University
2 shared publications
Latest Publications
- 1 May 2013
- Published by Elsevier in Cancer Letters
- Vol. 331 (2) , 230-238
MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma
- 1 May 2013
- Published by Elsevier in Cancer Letters
- Vol. 331 (2) , 230-238
MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma
- Open Access
- 19 February 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 45
Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling
Background: The sixth leading class of cancer worldwide is head and neck cancer, which typically arise within the squamous epithelium of the oral mucosa. Human head and neck squamous cell carcinoma (HNSCC) is known to be difficult to treat and has only a 50% five-year survival rate. With HNSCC, novel therapeutics are needed along with a means of rapidly screening anti-cancer agents in vivo, such as mouse models. Methods: In order to develop new animal models of cancer to test safety and efficacy of novel therapeutic agents for human HNSCC, tumors resembling clinical cases of human HNSCC were induced in the head and neck epithelium of a genetically engineered mouse model. This mouse model was generated by conditional deletion of two tumor suppressors, Transforming Growth Factor-β Receptor 1 (TGFβRI) and Phosphatase and Tensin homolog (PTEN), in the oral epithelium. We discovered that the tumors derived from these Tgfbr1/Pten double conditional knockout (2cKO) mice over-expressed IL-13Rα2, a high affinity receptor for IL-13 that can function as a tumor antigen. To demonstrate a proof-of-concept that targeted therapy against IL-13Rα2 expression would have any antitumor efficacy in this spontaneous tumor model, these mice were treated systemically with IL-13-PE, a recombinant immunotoxin consisting of IL-13 fused to the Pseudomonas exotoxin A. Results: Tgfbr1/Pten 2cKO mice when treated with IL-13-PE displayed significantly increased survival when compared to the untreated control mice. The untreated mice exhibited weight loss, particularly with the rapid onset of tongue tumors, but the treated mice gained weight while on IL-13-PE therapy and showed no clinical signs of toxicity due to the immunotoxin. Expression of IL-13Rα2 in tumors was significantly decreased with IL-13-PE treatment as compared to the controls and the number of myeloid-derived suppressor cells (MDSC) was also significantly reduced in the spleens of the IL-13-PE treated mice. Conclusions: Our study demonstrates that the Tgfbr1/Pten 2cKO mouse model of human HNSCC is a useful model for assessing antitumor activity of new cancer therapeutic agents, and that IL-13-PE has therapeutic potential to treat human head and neck cancer.
- 19 February 2013
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 45
Open AccessTargeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling
Background: The sixth leading class of cancer worldwide is head and neck cancer, which typically arise within the squamous epithelium of the oral mucosa. Human head and neck squamous cell carcinoma (HNSCC) is known to be difficult to treat and has only a 50% five-year survival rate. With HNSCC, novel therapeutics are needed along with a means of rapidly screening anti-cancer agents in vivo, such as mouse models. Methods: In order to develop new animal models of cancer to test safety and efficacy of novel therapeutic agents for human HNSCC, tumors resembling clinical cases of human HNSCC were induced in the head and neck epithelium of a genetically engineered mouse model. This mouse model was generated by conditional deletion of two tumor suppressors, Transforming Growth Factor-β Receptor 1 (TGFβRI) and Phosphatase and Tensin homolog (PTEN), in the oral epithelium. We discovered that the tumors derived from these Tgfbr1/Pten double conditional knockout (2cKO) mice over-expressed IL-13Rα2, a high affinity receptor for IL-13 that can function as a tumor antigen. To demonstrate a proof-of-concept that targeted therapy against IL-13Rα2 expression would have any antitumor efficacy in this spontaneous tumor model, these mice were treated systemically with IL-13-PE, a recombinant immunotoxin consisting of IL-13 fused to the Pseudomonas exotoxin A. Results: Tgfbr1/Pten 2cKO mice when treated with IL-13-PE displayed significantly increased survival when compared to the untreated control mice. The untreated mice exhibited weight loss, particularly with the rapid onset of tongue tumors, but the treated mice gained weight while on IL-13-PE therapy and showed no clinical signs of toxicity due to the immunotoxin. Expression of IL-13Rα2 in tumors was significantly decreased with IL-13-PE treatment as compared to the controls and the number of myeloid-derived suppressor cells (MDSC) was also significantly reduced in the spleens of the IL-13-PE treated mice. Conclusions: Our study demonstrates that the Tgfbr1/Pten 2cKO mouse model of human HNSCC is a useful model for assessing antitumor activity of new cancer therapeutic agents, and that IL-13-PE has therapeutic potential to treat human head and neck cancer.
- 19 October 2010
- Published by Wiley in Histopathology
- Vol. 57 (4) , 622-632
LMO2 promotes angiogenesis probably by up‐regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangioma
Sun Z‐J, Cai Y, Chen G, Wang R, Jia J, Chen X‐M, Zheng L‐W & Zhao Y‐F (2010)Histopathology57, 622–632 LMO2 promotes angiogenesis probably by up‐regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangiomaAims: Infantile haemangiomas (IHs) are common benign vascular tumours distinctive for their perinatal presentation, rapid growth during the first year of life and subsequent slow involution. Recent research has indicated that endothelial cells of haemangiomas express LIM‐only protein 2 (LMO2). The aim of this study was to investigate the role of LMO2 in the pathogenesis of IHs was investigated.Methods and results: Immunoreactivity of LMO2 was assessed in specimens of 19 IH. Stable transfection of LMO2 into human endothelial cell lines (EAhy926) was performed to evaluate the role of LMO2 in terms of the change in cell proliferation, cell cycle and cell migration as well as the expression level of angiogenic factors. Immunoreactivity for LMO2 was detected in all IH specimens, specifically in the nucleus of the endothelial cells. The intensity of LMO2 immunostaining decreased significantly from proliferative to involuting stages. Furthermore, the overexpression of LMO2 enhanced the proliferation and migration of the endothelial cells and promoted G0/G1–S‐phase transitionin vitro, together with an up‐regulation of bFGF expression.Conclusions: LMO2 probably promotes angiogenesis by up‐regulation of bFGF expression and thereby consequently influences progression of IH.
- 19 October 2010
- Published by Wiley in Histopathology
- Vol. 57 (4) , 622-632
LMO2 promotes angiogenesis probably by up‐regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangioma
Sun Z‐J, Cai Y, Chen G, Wang R, Jia J, Chen X‐M, Zheng L‐W & Zhao Y‐F (2010)Histopathology57, 622–632 LMO2 promotes angiogenesis probably by up‐regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangiomaAims: Infantile haemangiomas (IHs) are common benign vascular tumours distinctive for their perinatal presentation, rapid growth during the first year of life and subsequent slow involution. Recent research has indicated that endothelial cells of haemangiomas express LIM‐only protein 2 (LMO2). The aim of this study was to investigate the role of LMO2 in the pathogenesis of IHs was investigated.Methods and results: Immunoreactivity of LMO2 was assessed in specimens of 19 IH. Stable transfection of LMO2 into human endothelial cell lines (EAhy926) was performed to evaluate the role of LMO2 in terms of the change in cell proliferation, cell cycle and cell migration as well as the expression level of angiogenic factors. Immunoreactivity for LMO2 was detected in all IH specimens, specifically in the nucleus of the endothelial cells. The intensity of LMO2 immunostaining decreased significantly from proliferative to involuting stages. Furthermore, the overexpression of LMO2 enhanced the proliferation and migration of the endothelial cells and promoted G0/G1–S‐phase transitionin vitro, together with an up‐regulation of bFGF expression.Conclusions: LMO2 probably promotes angiogenesis by up‐regulation of bFGF expression and thereby consequently influences progression of IH.
- 1 September 2010
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 68 (9) , 2122-2128
Aneurysmal Bone Cysts of the Jaws: Analysis of 17 Cases
- 1 September 2010
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 68 (9) , 2122-2128
Aneurysmal Bone Cysts of the Jaws: Analysis of 17 Cases
- 1 November 2009
- Published by Elsevier in Pathology - Research and Practice
- Vol. 205 (11) , 753-757
Epithelioid angiomatous nodule of head and neck
- 1 November 2009
- Published by Elsevier in Pathology - Research and Practice
- Vol. 205 (11) , 753-757
Epithelioid angiomatous nodule of head and neck
- 1 September 2009
- Published by Elsevier in Oral Oncology
- Vol. 45 (9) , 752-759
Desmoplastic ameloblastoma – A review
- 1 September 2009
- Published by Elsevier in Oral Oncology
- Vol. 45 (9) , 752-759
Desmoplastic ameloblastoma – A review
- 7 July 2009
- Published by Springer Nature in Skeletal Radiology
- Vol. 38 (9) , 903-909
Central giant cell granuloma of the jaws: clinical and radiological evaluation of 22 cases
Objective The objective was to investigate the clinical and radiological characteristics of central giant cell granulomas (CGCGs) of the jaws. Methods A retrospective analysis of a 20-year database was performed regarding both clinical and radiological features of 22 patients affected with CGCGs of the jaws. Results Fourteen women and 8 men were included with the age range of 7–81 years (mean 31.7 years). Among the 22 lesions, 16 were located in the mandible and 6 in the maxilla. Painless swelling was the most common clinical feature in 18 of all cases. Limited mouth opening was noted in 2 patients where the lesions involved the condyle. Radiographically, 13 lesions were homogeneously osteolytic and 9 lesions were trabeculated. Fifteen lesions were unilocular and 14 lesions presented with well-defined but not sclerotic margins. CT images in 5 patients clearly showed the trabeculation within the lesions. The follow-up ranged from 1.5 to 11 years with a mean period of 5 years. Three out of 9 aggressive and 1 out of 13 nonaggressive lesions developed recurrence. Conclusions Diagnosis of CGCGs of the jaws depends on both correct interpretation of clinical, radiographic and pathological data. Differentiation between aggressive and nonaggressive CGCGs should be considered to improve individual treatment planning.
- 7 July 2009
- Published by Springer Nature in Skeletal Radiology
- Vol. 38 (9) , 903-909
Central giant cell granuloma of the jaws: clinical and radiological evaluation of 22 cases
Objective The objective was to investigate the clinical and radiological characteristics of central giant cell granulomas (CGCGs) of the jaws. Methods A retrospective analysis of a 20-year database was performed regarding both clinical and radiological features of 22 patients affected with CGCGs of the jaws. Results Fourteen women and 8 men were included with the age range of 7–81 years (mean 31.7 years). Among the 22 lesions, 16 were located in the mandible and 6 in the maxilla. Painless swelling was the most common clinical feature in 18 of all cases. Limited mouth opening was noted in 2 patients where the lesions involved the condyle. Radiographically, 13 lesions were homogeneously osteolytic and 9 lesions were trabeculated. Fifteen lesions were unilocular and 14 lesions presented with well-defined but not sclerotic margins. CT images in 5 patients clearly showed the trabeculation within the lesions. The follow-up ranged from 1.5 to 11 years with a mean period of 5 years. Three out of 9 aggressive and 1 out of 13 nonaggressive lesions developed recurrence. Conclusions Diagnosis of CGCGs of the jaws depends on both correct interpretation of clinical, radiographic and pathological data. Differentiation between aggressive and nonaggressive CGCGs should be considered to improve individual treatment planning.
- 19 February 2009
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 17 (4) , 311-322
Review Article: Aneurysmal Bone Cysts of the Jaws
Aneurysmal bone cyst (ABC) is a osteolytic bone lesion that rarely involves the jaws. To date, a total of 92 cases of JABCs have been described in detail in English literature. They prevalently occur in the first 2 decades (72.8%) with slight female predilection. It affects the mandible more often (68.5%) with a predominant location in the mandibular ramus (31.3%) and its posterior regions (20.4%). A painless (54.7%) or painful (43.2%) bone swelling is the most frequent clinical sign. Radiologically 93.8% of the lesions present as a radiolucency; in 69.4% multilocular in appearance. 15.2% of JABCs were secondary in nature, including 8 cases associated with fibrous dysplasia. The recurrence rate (13.3%) did not differ significantly when comparing the surgical technique (curettage, 15.2%; resection, 11.8%). JABCs are known for their different clinical and radiographic features, therefore often posing a diagnostic dilemma. Some JABC's may be secondary in nature. Careful curettage is considered to be suitable as treatment for JABCs.
- 19 February 2009
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 17 (4) , 311-322
Review Article: Aneurysmal Bone Cysts of the Jaws
Aneurysmal bone cyst (ABC) is a osteolytic bone lesion that rarely involves the jaws. To date, a total of 92 cases of JABCs have been described in detail in English literature. They prevalently occur in the first 2 decades (72.8%) with slight female predilection. It affects the mandible more often (68.5%) with a predominant location in the mandibular ramus (31.3%) and its posterior regions (20.4%). A painless (54.7%) or painful (43.2%) bone swelling is the most frequent clinical sign. Radiologically 93.8% of the lesions present as a radiolucency; in 69.4% multilocular in appearance. 15.2% of JABCs were secondary in nature, including 8 cases associated with fibrous dysplasia. The recurrence rate (13.3%) did not differ significantly when comparing the surgical technique (curettage, 15.2%; resection, 11.8%). JABCs are known for their different clinical and radiographic features, therefore often posing a diagnostic dilemma. Some JABC's may be secondary in nature. Careful curettage is considered to be suitable as treatment for JABCs.